drugset / Trial / NCT00140725

Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positive Chronic Hepatitis B Virus (HBV)

NCT00140725

Phase 3 Completed 160 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a single-centre prospective randomised study comparing the virological and histological response of HBV infection to lamivudine in combination with interferon versus lamivudine alone.

Timeline

Start
2000-04
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Lamivudine Other / unclassified
Subject Polyethylene glyco-interferon alfa-2b Unknown